The Journal of Urology
Volume 184, Issue 2 , Pages 453-458 , August 2010

Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract

  • Vitaly Margulis

      Affiliations

    • UT Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75390-9110
    • Equal study contribution.
    • Nothing to disclose.
    • ,
  • Ramy F. Youssef

      Affiliations

    • UT Southwestern Medical Center, Dallas, Texas
    • Equal study contribution.
    • Nothing to disclose.
    • ,
  • Pierre I. Karakiewicz

      Affiliations

    • University of Montreal, Montreal, Quebec, Canada
    • Nothing to disclose.
    • ,
  • Yair Lotan

      Affiliations

    • UT Southwestern Medical Center, Dallas, Texas
    • Financial interest and/or other relationship with Inverness, Abbott and Matritech.
    • ,
  • Christopher G. Wood

      Affiliations

    • UT M.D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with Antigenics Inc., Kidney Cancer Association, Amgen and Pfizer Speaker's Bureau.
    • ,
  • Richard Zigeuner

      Affiliations

    • University of Graz, Graz, Austria
    • Financial interest and/or other relationship with Inverness, Abbott and Matritech.
    • ,
  • Eiji Kikuchi

      Affiliations

    • Keio University School of Medicine, Tokyo, Japan
    • Nothing to disclose.
    • ,
  • Alon Weizer

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • Nothing to disclose.
    • ,
  • Jay D. Raman

      Affiliations

    • Cornell University, New York, New York
    • Nothing to disclose.
    • ,
  • Mesut Remzi

      Affiliations

    • Medical University of Vienna, Vienna, Austria
    • Nothing to disclose.
    • ,
  • Marco Roscigno

      Affiliations

    • Vita-Salute University, Milan, Italy
    • Equal study contribution.
    • ,
  • Francesco Montorsi

      Affiliations

    • Vita-Salute University, Milan, Italy
    • Nothing to disclose.
    • ,
  • Christian Bolenz

      Affiliations

    • Universitätsklinikum Mannheim, Mannheim, Germany
    • Nothing to disclose.
    • ,
  • Wassim Kassouf

      Affiliations

    • McGill University, Montreal, Quebec, Canada
    • Nothing to disclose.
    • ,
  • Shahrokh F. Shariat

      Affiliations

    • UT Southwestern Medical Center, Dallas, Texas
    • Nothing to disclose.
    • ,
  • Upper Tract Urothelial Carcinoma Collaborative Group

Received 26 October 2009

References 

  1. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol. 2008;15:127
  2. Koukourakis G, Zacharias G, Koukourakis M, et al. Comprehensive management of upper tract urothelial carcinoma. Adv Urol. 2009;Epub ahead of print
  3. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224
  4. Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol. 2007;4:432
  5. O'Donnell PH, Stadler WM. The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol. 2009;Epub ahead of print
  6. Brown GA, Busby JE, Wood CG, et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. BJU Int. 2006;98:1176
  7. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer (AJCC) Staging Manual. In: 6th ed.. Philadelphia: Springer; 2002;
  8. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder (Bladder Consensus Conference Committee). Am J Surg Pathol. 1998;22:1435
  9. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361
  10. Bradley E, Tibshirani RJ. Monographs on Statistics and Applied Probability: An Introduction to the Bootstrap. Boca Raton: Chapman and Hall/CRC; 1993;
  11. Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54:1127
  12. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859
  13. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927
  14. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561
  15. Kondo T, Nakazawa H, Ito F, et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol. 2007;178:1212
  16. Roscigno M, Shariat SF, Margulis V, et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 2009;181:2482
  17. Brausi MA, Gavioli M, De Luca G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol. 2007;52:1414
  18. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133:403
  19. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602
  20. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001;19:4005
  21. Scolieri MJ, Paik ML, Brown SL, et al. Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology. 2000;56:930
  22. Planz B, George R, Adam G, et al. Computed tomography for detection and staging of transitional cell carcinoma of the upper urinary tract. Eur Urol. 1995;27:146
  23. Tavora F, Fajardo DA, Lee TK, et al. Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol. 2009;33:1540
  24. Remzi M, Haitel A, Margulis V, et al. Tumor architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009;103:307
  25. Akdogan B, Dogan HS, Eskicorapci SY, et al. Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. J Urol. 2006;176:48
  26. Park S, Hong B, Kim CS, et al. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol. 2004;171:621
  27. Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2009;Epub ahead of print
  28. Isbarn H, Jeldres C, Shariat SF, et al. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol. 2009;182:2177

 Study received institutional review board approval.

 Editor's Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 810 and 811.

PII: S0022-5347(10)03270-2

doi: 10.1016/j.juro.2010.03.142

The Journal of Urology
Volume 184, Issue 2 , Pages 453-458 , August 2010

Article Tools

* Image Usage & Resolution